Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 21, 2023 06:00 ET | Source: Research Nester

Cardiometabolic Drugs Market revenue to exceed USD 72 Billion by 2035, says Research Nester

New York, Aug. 21, 2023 (GLOBE NEWSWIRE) -- The global Cardiometabolic Drugs Market size is projected to expand at ~ 6% CAGR between 2023 and 2035. The market is expected to garner a revenue of USD...
August 05, 2021 06:50 ET | Source: Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals Reports 2021 Second Quarter Financial Results and Provides Corporate Update

CONSHOHOCKEN, Pa., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) reports today its second quarter 2021 financial results and provides a summary of corporate...
March 23, 2021 08:03 ET | Source: Research and Markets

Global Dyslipidemia Disease Analysis 2020-2027 - Market is Poised to Resume Steady Growth Due to the Introduction of Novel Agents

Dublin, March 23, 2021 (GLOBE NEWSWIRE) -- The "Disease Analysis: Dyslipidemia" report has been added to ResearchAndMarkets.com's offering. The report estimates that in 2018, there were...
February 25, 2021 06:50 ET | Source: Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals Reports 2020 Fourth Quarter and Full Year Financial Results and Highlights

WEST CONSHOHOCKEN, Pa., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) announced today its fourth quarter and full year 2020 financial results and highlights. “We...
November 13, 2020 06:50 ET | Source: Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals Highlights Presentations at The Liver Meeting Digital Experience™, The American Association for the Study of Liver Diseases Meeting November 13, 2020, Including NASH Expert Insights on the Ongoing Open Label Arm of Resmetirom 52-Week Phase 3 MAESTRO-NAFLD-1 Trial

Dr. Stephen Harrison will present Resmetirom for the Treatment of NASH: Early Data from the Phase 3 MAESTRO Clinical Trials | The Liver Meeting Digital Experience™, AASLD Product Theater on Friday,...
November 05, 2020 06:50 ET | Source: Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals Announces Completion of Enrollment in Phase 3 MAESTRO NAFLD-1 Trial and Reports 2020 Third Quarter Financial Results and Highlights

CONSHOHOCKEN, Pa., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) announced today that it completed enrollment in its MAESTRO NAFLD-1 clinical trial of resmetirom in...
August 26, 2020 06:50 ET | Source: Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals to Present Secondary Analyses of Data from Phase 2 NASH Study of Resmetirom and Symposium at the Digital International Liver Congress™ 2020

CONSHOHOCKEN, Pa., Aug. 26, 2020 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) announced today that on Friday, August 28, 2020 at the Digital International Liver Congress™ 2020,...
August 11, 2020 12:00 ET | Source: Cardiometabolic Health Congress

CMHC Concludes CMHC West Live Online: Complexities in Cardiometabolic Care.

Boca Raton, FL, Aug. 11, 2020 (GLOBE NEWSWIRE) -- CMHC Concludes CMHC West Live Online: Complexities in Cardiometabolic Care. CMHC West Live Online: Complexities in Cardiometabolic Care concluded...
August 06, 2020 06:50 ET | Source: Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals Reports 2020 Second Quarter Financial Results and Highlights

CONSHOHOCKEN, Pa., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today announced its second quarter 2020 financial results and highlights: “The Madrigal team and...
July 10, 2020 12:30 ET | Source: National Lipid Association

National Lipid Association Releases Official Scientific Statement on Genetic Testing in Dyslipidemia

JACKSONVILLE, Fla., July 10, 2020 (GLOBE NEWSWIRE) -- The National Lipid Association (NLA) today announced the release of its official scientific statement on the use of genetic testing in the...

Next Page keyboard_arrow_right